CIRCA Scientific Welcomes Vafa Jamali to Its Board of Directors to Drive Innovation

CIRCA Scientific Welcomes Vafa Jamali to Its Board of Directors

CIRCA Scientific, a leader in the field of medical technology, announced a significant addition to its executive team with the appointment of Vafa Jamali to its Board of Directors. This strategic move is expected to enhance the company’s commitment to developing innovative solutions in the cardiac medical device sector.

Vafa Jamali brings over three decades of extensive experience in the medical technology industry, marked by a progressive career at prominent firms like ZimVie, Medtronic, Covidien, and Cardinal Health. His proven track record includes not only operational excellence but also strategic growth and innovation in diverse healthcare markets. Jamali's deep understanding of the medical device landscape positions him as a valuable asset for CIRCA Scientific as it navigates the increasingly complex world of cardiac technologies.

Throughout his career, Mr. Jamali has significantly influenced the strategic direction of numerous recognized organizations. His leadership at Baylis Medical Technologies is noteworthy; he played a crucial role in steering the company's growth strategy, culminating in the successful divestment of its transseptal crossing portfolio to Boston Scientific for an impressive $1.75 billion in 2022. This experience will undoubtedly inform his contributions to CIRCA Scientific’s Board.

Lee Geist, the President and CEO of CIRCA Scientific, expressed enthusiasm about Jamali’s addition to the board, noting, "Vafa is a highly respected leader with deep experience scaling global medical technology businesses and bringing innovative products to market. As we continue executing our CardioCentric™ strategy and expanding our portfolio of advanced cardiac access technologies, his strategic insight and leadership experience will be invaluable."

This appointment comes at a pivotal moment for CIRCA Scientific as the company expands its portfolio to include advanced procedural solutions for cardiac electrophysiology and interventional cardiology. The recent launches of the CrossWise™ RF Transseptal Access System and the PeriCross™ Epicardial Access Kit are designed to enhance physicians' control, efficiency, and precision during complex procedures. These innovations build on CIRCA's established leadership in esophageal temperature monitoring, where its cutting-edge technologies have set safety and accuracy benchmarks in the field.

In his remarks, Jamali stated, "CIRCA Scientific has built a compelling portfolio of access and monitoring solutions for electrophysiologists and interventional cardiologists, positioning it well for meaningful growth. I am excited to join the board and work with the leadership team to help advance the company's mission of improving procedural outcomes for physicians and patients."

As CIRCA Scientific continues to expand and commercialize its innovative access platforms, Mr. Jamali's perspective as a seasoned medtech operator will be instrumental in guiding the next phase of growth. The company’s forward-looking CardioCentric™ approach signifies a strong commitment to enhancing procedural success and patient care through innovation.

In summary, Vafa Jamali's appointment to the Board of Directors at CIRCA Scientific embodies a pivotal step toward bolstering the organization's strategic capabilities in the burgeoning market of cardiac technology. As the company looks to leverage its expertise to improve medical outcomes for both physicians and patients, the leadership of seasoned professionals like Jamali will play a crucial role.